Vector BioPharma is a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery, to improve treatments for patients. Incorporating cutting-edge platform technologies, from world-class academic research at the University of Zürich, Vector BioPharma uses engineered adenoviral vectors to achieve cell- and tissue-specific delivery, and tunable expression of genes and regulators with unprecedented precision.
Vector BioPharma’s cutting-edge gene precision delivery technology will transform the safety, efficacy, and specificity of biologics and cell therapies.
Our Shielded, Retargeted Adenovirus (SHREAD) platform, harnesses the non-replicative, high-capacity properties of adenoviral vectors (HCAdVs) combined with exogenous, high-avidity adapter proteins to redirect delivery of DNA encoding therapeutics to defined biomarkers on the target cell or tissue, in a highly controlled manner.
This allows for the local production of highly potent drugs with greatly reduced risk of systemic toxicities.
Smith SN et al. The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody. Proc National Acad Sci USA (2021)
Brücher D et al. iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy. Mol Ther Methods Clin Dev (2021)
Schmid M et al. Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Comm (2018)
Dreier B et al. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc National Acad Sci USA (2013)
Vector BioPharma is a pharmaceutical company developing its own therapeutic products. The Company’s proprietary delivery technology is available to license by innovative companies with new modalities.
We are looking to partner with pioneers in the fields of cell therapies, precision medicine, and academic researchers to revolutionize gene delivery.
Vector BioPharma will commercialize its technology via the development of therapeutics and is initially focused on immuno-oncology. The Company’s adenoviral vectors can be used to deliver genes and gene regulators to facilitate the use of next-generation treatment modalities working with DNA, including in-situ expression of immune checkpoint inhibitors and CAR T cell therapies.
Following a successful Series A round in 2021, Vector Biopharma will continue to invest in technology development. We welcome inquiries from investors ahead of our Series B investment round.
A new technology developed by UZH researchers enables the body to produce therapeutic agents on demand at the exact location where they are needed. The innovation could reduce the side effects of cancer therapy and may hold the solution to better delivery of Covid-related therapies directly to the lungs.